Treating a Lab Value Two Trials Already Tested and Refuted
A referring physician wants to add allopurinol for a progressing CKD patient's elevated uric acid, reasoning from a mechanism that once looked plausible. Two negative trials since then already asked this exact question directly.
An uric acid of 8.9 mg/dL, flagged by a reviewing primary care physician rather than by Teresa V. herself, is what reopened a question nephrology had long since stopped asking. She is a 59-year-old woman diagnosed with focal segmental glomerulosclerosis eleven years ago after an unexplained bout of leg swelling sent her to an emergency room, and has followed with nephrology ever since. Her disease has been managed reasonably well — blood pressure at goal, proteinuria meaningfully reduced from its peak — but her eGFR has continued a slow, real decline over the past two years, from 41 to 34, despite that otherwise optimized picture. Her primary care physician, reviewing her chart before a referral visit, noticed her uric acid has run consistently elevated at 8.9 mg/dL, with no history of gout attacks or joint symptoms, and asked directly whether starting allopurinol made sense — reasoning that an elevated, modifiable lab value mechanistically linked to kidney injury seemed worth treating in a patient who is progressing despite everything else already being addressed.
That reasoning was genuinely plausible for years, built on real epidemiologic associations between hyperuricemia and CKD progression and a coherent mechanism — uric acid-driven endothelial dysfunction and intrarenal vasoconstriction. Two trials have since tested it directly rather than by association. PERL randomized patients with type 1 diabetes and CKD to allopurinol or placebo and found no difference in the rate of eGFR decline despite successfully lowering uric acid. CKD-FIX, in a broader CKD population, found the same null result on its primary renal endpoint. Both trials did exactly what the mechanistic story predicted they should do to the lab value — and neither changed the trajectory the story was supposed to explain.
An elevated uric acid, and two trials that already asked whether treating it helps
I raised allopurinol because her eGFR keeps falling despite everything else being managed well, and 8.9 is a genuinely elevated, modifiable number with a real mechanistic link to kidney injury. Treating it seemed like a reasonable next lever to pull.
I understand the instinct, and I'd have shared it before these trials existed. But PERL and CKD-FIX didn't just study hyperuricemia's association with CKD from a distance — they randomized patients to allopurinol specifically to test whether lowering it slows eGFR decline, and both found no benefit on the primary renal endpoint, despite the drug doing exactly what it's supposed to do to the lab value itself. That's a mechanism that's been directly tested and came back negative, not one that's simply never been studied at scale.
I want to be fair to the reasoning behind the referral — it was genuinely sound before these trials reported. It just isn't sound anymore, specifically because it's been tested.
Worth adding the other half of why this isn't a low-cost precaution: allopurinol carries a real risk of severe cutaneous adverse reactions, a risk that rises specifically with reduced renal clearance of its active metabolite — precisely the situation Teresa is in. Absent demonstrated benefit, that's not a risk worth taking on her behalf. The actual lever left for her progression is what's already working — continued optimization of her existing regimen — not a new drug the evidence has already weighed in on.
Agreed, with the primary care physician's initial reasoning acknowledged as sound before the trial evidence was reviewed together: allopurinol not started, existing regimen continued, and the uric acid value itself no longer flagged as an actionable target.
No open disagreement remained once PERL and CKD-FIX were reviewed directly — the case closed on genuine consensus rather than a residual split.